Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RAPT Therapeutics ( (RAPT) ) has provided an announcement.
On January 14, 2026, RAPT Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress and plans for its lead drug candidate ozureprubart, which it positions as a potentially best-in-class successor to omalizumab in allergic diseases. The company reported positive Phase 2 data in chronic spontaneous urticaria during 2025, initiated a Phase 2b food allergy trial expected to read out in the first half of 2027, and outlined plans to begin a Phase 3 chronic spontaneous urticaria trial in the second half of 2026, targeting multibillion-dollar U.S. market opportunities in food allergy and urticaria. RAPT also emphasized strengthened corporate and financial footing through a $265 million follow-on offering extending its cash runway to mid-2028, key leadership appointments with commercialization and allergy expertise, and expansion of its pipeline with a next-generation CCR4 candidate, signaling an aggressive push to solidify its position in the competitive inflammatory disease space and de-risk its late-stage development program for stakeholders.
The most recent analyst rating on (RAPT) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.
Spark’s Take on RAPT Stock
According to Spark, TipRanks’ AI Analyst, RAPT is a Neutral.
Score reflects a strong technical uptrend and meaningful positive corporate events (extended funding runway and positive Phase 2 data), partially offset by weak financial performance driven by $0 revenue, sizable ongoing losses, and heavy negative free cash flow. Valuation provides limited support given the negative P/E and no dividend yield data.
To see Spark’s full report on RAPT stock, click here.
More about RAPT Therapeutics
RAPT Therapeutics is a clinical-stage biotechnology company developing transformative therapies for high-value inflammatory diseases, with a primary focus on allergic conditions such as food allergies and chronic spontaneous urticaria. Its lead candidate, ozureprubart (RPT904), is a next-generation, anti-IgE “bio-better” antibody to omalizumab, engineered for less frequent dosing, improved compliance, and the potential for broader efficacy, particularly in large and growing U.S. markets for food allergy and urticaria treatment. The company also maintains an oncology and inflammation pipeline, including CCR4 antagonists, and reports a cash runway sufficient to fund multiple upcoming clinical milestones.
Average Trading Volume: 506,147
Technical Sentiment Signal: Buy
Current Market Cap: $953.3M
See more data about RAPT stock on TipRanks’ Stock Analysis page.